BEAM Dec 2024 40.000 call
- GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on Jun
- Insider Monkey
15 Best ARK Stocks To Buy Now
In this article, we will take a look at the 15 best ARK stocks to buy now. To see more such companies, go directly to 5 Best ARK Stocks To Buy Now. Cathie Wood is one of the most polarizing, and prominent figures on Wall Street. With over three decades of experience in the financial sector, […]
- Simply Wall St.
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders are probably feeling a little disappointed, since its shares fell...
